Cart
sales@molnova.com
AF-710B
CAS No. 1235733-73-9
AF-710B( —— )
Catalog No. M33961 CAS No. 1235733-73-9
AF-710B is a specific variant of M1 muscarinic and Sigma-1 receptor agonist used in the study of neurological disorders such as Alzheimer's disease dementia and schizophrenia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 470 | In Stock |
|
| 5MG | 751 | In Stock |
|
| 10MG | 1064 | In Stock |
|
| 25MG | 1587 | In Stock |
|
| 50MG | 2027 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAF-710B
-
NoteResearch use only, not for human use.
-
Brief DescriptionAF-710B is a specific variant of M1 muscarinic and Sigma-1 receptor agonist used in the study of neurological disorders such as Alzheimer's disease dementia and schizophrenia.
-
DescriptionAF710B is a highly potent and selective allosteric M1 muscarinic and σ1 receptor agonist. AF710B can be used for the research of Alzheimer’s disease.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAutophagy
-
TargetSigma receptor
-
RecptorSigma receptor | AChR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1235733-73-9
-
Formula Weight357.51
-
Molecular FormulaC20H27N3OS
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(N1CC2(SC1C)CCN(C)CC2)CCC3=CNC=4C=CC=CC43
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Fisher A, et al. AF710B, a Novel M1/σ1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer’s Disease. Neurodegener Dis. 2016;16(1-2):95-110.?
molnova catalog
related products
-
Opipramol
Opipramol (Ensidon) is a compound with antidepressant activity that attenuates cocaine-seeking behavior in a rat model of self-administration.
-
UNC-0642
UNC0642 is an effective and specific G9a/GLP inhibitor (IC50< 2.5 nM).
-
Glycerol phenylbutyr...
Glycerol phenylbutyrate (GPB) is a new generation ammonia scavenger drug and it also is a sigma-2 (σ2) receptor ligand (pKi: 8.02).Glycerol phenylbutyrate may have therapeutic potential in additional conditions such as chronic hepatic encephalopathy or other inherited metabolic disorders. Glycerol phenylbutyrate also has the potential for the treatment of hyperammonemia.
